Unlike some medications, GLP-1 agonists like semaglutide and tirzepatide do not require a medically mandatory taper there is no withdrawal syndrome or physical dependence risk in the traditional sense
Liver Markers One health risk of obesity is fatty liver disease, which is why testing liver markers may be helpful for those on a GLP-1
GLP-1R agonists exhibit protective and regulatory effects on blood glucose levels but have been linked to the inhibition of tumor cell proliferation in most cancer cases, as seen in vitro and summarized in Table 1 [51, 73]
In Arkansas, semaglutide injections can be given by professionals with the titles MD, DO, NP, PA, RN, LPN
To start, let's talk about needle sizing
Large-scale randomized controlled trials such as SUSTAIN, SELECT, and SURPASS, as well as multiple realworld cohort studies, have consistently reported no significant increase in the risk of depression, suicidality, or psychiatric hospitalization compared with placebo or other anti-diabetic agents [110-112]